heat-inactivated bacteria
Vaccineexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
4
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01734811)
Timeline
Indications
Mechanism of action
- StaphylococcusImmunity, active
Staphylococcus immunity, active
- Pseudomonas aeruginosaImmunity, active
Pseudomonas aeruginosa immunity, active
- Salmonella sp.Immunity, active
Salmonella sp. immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mv130
- mv140
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05208060 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2022 | Inmunotek S.L., Universidad Complutense de Madrid |
| NCT04452643 | Phase 3 | Oct 31, 2020 | Inmunotek S.L. |
| NCT02543827 | Phase 3 | Nov 1, 2015 | Inmunotek S.L. |
| NCT01842360 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2013 | Inmunotek S.L. |
| NCT01734811 | Phase 3 | Oct 1, 2012 | Inmunotek S.L., Unidad de Investigacion Medica en Epidemiologia Clinica |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inmunotek S.L. | For profit | 5 | 5 | 2 | 2012 |
| Unidad de Investigacion Medica en Epidemiologia Clinica | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Universidad Complutense de Madrid | Academic/Hospital | 1 | 0 | 1 | 2022 |
3 organizations
Page 1 / 1